Browsing Tag
Medtronic plc
16 posts
Can the BACKBEAT trial validate a new category of device-driven hypertension therapy?
What does the BACKBEAT trial mean for Medtronic plc and Orchestra BioMed Holdings, Inc.? Discover the future of device-driven hypertension therapy.
Medtronic expands cardiac ablation ambitions as Sphere-9 gains FDA Breakthrough Device pathway for VT
Medtronic’s Affera push is no longer just an AFib story. VT data may decide whether Sphere-9 becomes a broader ablation platform.
Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies
Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence?
Is MiniMed (Nasdaq: MMED) worth watching after its IPO slide and before June earnings?
MiniMed (Nasdaq: MMED) is down from its IPO price. Read what June earnings, new product launches, and analyst targets could mean next.
A $560m test for the diabetes device market as MiniMed prepares to trade on Nasdaq
MiniMed prices its IPO at $20 per share, raising $560M as Medtronic plc spins out its diabetes unit. Discover what the move means for the diabetes technology market.
FDA clearance of Stealth AXiS highlights growing demand for unified spine surgery platforms
Medtronic plc wins FDA clearance for Stealth AXiS. Discover how unified spine robotics could reshape hospital strategy and investor expectations.
What Medtronic’s Stealth AXiS FDA clearance signals for surgical navigation and robotics competition
Medtronic has secured FDA clearance for Stealth AXiS. Find out how this move strengthens its surgical navigation strategy and long-term competitive position.
Medtronic invests in Anteris (ASX: AVR) to fund DurAVR trial and TAVR platform expansion
Anteris Technologies has raised USD 320M, including USD 90M from Medtronic, to fund its global DurAVR heart valve trial. Read what this means for TAVR competition.
MiniMed IPO: Medtronic (NYSE: MDT) to separate diabetes business with Nasdaq filing under MMED
Medtronic files IPO for MiniMed, its diabetes business. Find out what the Nasdaq listing means for the company’s strategy, margins, and the diabetes tech sector.
Can Hugo give hospitals a smarter surgical robot? FDA clearance puts Medtronic to test
Medtronic gets U.S. FDA clearance for Hugo RAS system in urologic surgery, unlocking new competition in robotic-assisted soft-tissue procedures. Read more.